Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 17 Jul 2024 03:04:59 +0200Thu, 06 Jun 2024 15:54:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0173/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip09-21-m01Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Pneumology-allergology, PIP number: P/0173/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip09-21-m01Thu, 06 Jun 2024 15:54:00 +0200Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0038/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip07-21Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Gastroentology-Hepatology, PIP number: P/0038/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip07-21Wed, 13 Mar 2024 18:21:31 +0100Human medicineOpinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Haematology-Hemostaseology, PIP number: P/0035/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip04-19Opinion/decision on a Paediatric investigation plan (PIP): Fasenra, Benralizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Haematology-Hemostaseology, PIP number: P/0035/2022https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001214-pip04-19Wed, 13 Mar 2024 17:47:14 +0100Human medicineHuman medicines European public assessment report (EPAR): Fasenra, benralizumab, Date of authorisation: 08/01/2018, Revision: 14, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/fasenraHuman medicines European public assessment report (EPAR): Fasenra, benralizumab, Date of authorisation: 08/01/2018, Revision: 14, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/fasenraTue, 13 Feb 2024 12:34:00 +0100Human medicineFasenra : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4433-aa_en.pdfFasenra : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4433-aa_en.pdfTue, 27 Aug 2019 01:00:00 +0200Human medicine